Table 3.
Cumulative Incidence (%) of Events Following Initiation of Select Second-Line Therapies
| Percent (95% Confidence Interval) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Event | Eltrombopag | Romiplostim | Rituximab | Splenectomy | ||||
| 3-Month | 6-Month | 3-Month | 6-Month | 3-Month | 6-Month | 3-Month | 6-Month | |
| Bleeding | ||||||||
| Any | 7 (1, 19) | 17 (6, 33) | 15 (6, 26) | 19 (9, 31) | 11 (5, 19) | 12 (6, 20) | 14 (3, 33) | 19 (6, 38) |
| Ecchymosis | – | – | – | – | 2 (0, 8) | 2 (0, 8) | – | – |
| Epistaxis | – | – | – | – | 1 (0, 6) | 1 (0, 6) | – | – |
| GI hemorrhage | – | 7 (1, 20) | 6 (2, 16) | 6 (2, 16) | 1 (0, 6) | 1 (0, 6) | – | – |
| Hematuria | 3 (0, 15) | 3 (0, 15) | – | 2 (0, 10) | 1 (0, 6) | 1 (0, 6) | – | – |
| Intracranial hemorrhage | – | – | – | – | 1 (0, 6) | 1 (0, 6) | 5 (0, 20) | 5 (0, 20) |
| Subsequent Treatment | ||||||||
| Any rescue therapya | 29 (14, 46) | 29 (14, 46) | 19 (9, 31) | 26 (14, 39) | 39 (29, 50) | 48 (36, 58) | 14 (3, 33) | 19 (6, 39) |
| IV steroids | 16 (6, 31) | 16 (6, 31) | 13 (5, 24) | 19 (9, 32) | 36 (26, 46) | 41 (31, 52) | 14 (3, 33) | 14 (3, 33) |
| IVIg | 23 (10, 39) | 23 (10, 39) | 8 (3, 18) | 8 (3, 18) | 10 (4, 17) | 15 (8, 24) | 5 (0, 20) | 10 (2, 27) |
| Oral steroids | 7 (1, 19) | 10 (2, 24) | 29 (17, 43) | 34 (21, 48) | 47 (36, 57) | 53 (42, 64) | 38 (18, 58) | 48 (25, 67) |
| Eltrombopag | – | – | 10 (4, 21) | 15 (6, 26) | 6 (2, 13) | 7 (3, 14) | 5 (0, 20) | 5 (0, 20) |
| Romiplostim | 16 (6, 31) | 23 (10, 39) | – | – | 15 (8, 23) | 18 (11, 28) | 10 (2, 27) | 24 (8, 44) |
| Rituximab | 13 (4, 27) | 13 (4, 27) | 10 (4, 21) | 15 (6, 26) | – | – | 10 (2, 27) | 14 (3, 33) |
| Splenectomy | – | 7 (1, 20) | 6 (2, 16) | 9 (3, 19) | 1 (0, 6) | 3 (0, 8) | – | – |
Notes: aRescue therapy was defined as IV anti-D, IVIg, IV steroids, or platelet transfusion.
Abbreviations: GI, gastrointestinal; IV, intravenous; IVIg, intravenous immunoglobulin.